title: The efficacy of midodrine hydrochloride in the treatment of children with vasovagal syncope.
abstract: OBJECTIVE
  To determine whether midodrine hydrochloride therapy can prevent vasovagal syncope (VVS) in pediatric patients.
  
  
  METHODS
  Children with recurrent syncope (n = 26) were randomly assigned into 2 groups. Group I comprised children given midodrine hydrochloride as first-line therapy in addition to conventional therapy, and group II comprised patients receiving conventional therapy only. Repeat head-up tilt (HUT) testing and follow-up of least 6 months were conducted to evaluate the therapeutic effectiveness and side effects of midodrine in treating VVS in children.
  
  
  RESULTS
  The HUT-based effective rate was significantly higher in group I than in group II (75% vs 20%; P < .05). During the follow-up period, the recurrence of syncope was significantly lower in group I than in group II (P < .05).
  
  
  CONCLUSIONS
  Midodrine hydrochlorate is effective in treating VVS in children, especially in preventing recurrent episodes. Few side effects were observed in the present study.
authors.affiliation: Department of Pediatrics and Institute of Cardiovascular Research, Peking University First Hospital and Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, People's Republic of China.
authors.forename: Zhang
authors.initials: Z
authors.lastname: Qingyou
authors.forename: Du
authors.initials: D
authors.lastname: Junbao
authors.forename: Tang
authors.initials: T
authors.lastname: Chaoshu
mesh_terms: D000293:Adolescent; D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D008879:Midodrine / Q000627:therapeutic use*; D019462:Syncope, Vasovagal / Q000517:prevention & control*
chemical_list: D000316:Adrenergic alpha-Agonists; D008879:Midodrine